Gene polymorphisms in TYMS, MTHFR, p53 and MDR1 as risk factors for breast cancer: A case-control study

Oncology Reports

Volumn 22, Issue 6, 2009, Pages 1425-1433

  Henriquez Hernandez L A ^a,b   Rosales, A Murias ^b   González, A Hernández ^b,c   De León, A Cabrera ^b,c,d   Diaz Chico B N ^a,b   De Santiago, M Mori ^b   Pérez, L Fernández ^a,b  

^a UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

^b HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^c HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^d UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

Breast cancer; MDR1; MTHFR; p53; PCR RFLP; Polymorphism; Risk factors; TSER

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ARGININE; MULTIDRUG RESISTANCE PROTEIN 1; PROLINE; PROTEIN P53; THYMIDYLATE SYNTHASE;

ADULT; ALLELE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CODON; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SMOKING; SPAIN;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CODON; FEMALE; GENE FREQUENCY; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; RISK FACTORS; THYMIDYLATE SYNTHASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70449356836     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000584     Document Type: Article

References (63)

1. Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150, 2006.
2. Maca-Meyer N, Villar J, Perez-Mendez L, Cabrera de Leon A and Flores C: A tale of aborigines, conquerors and slaves: Alu insertion polymorphisms and the peopling of Canary Islands. Ann Hum Genet 68: 600-605, 2004.
3. Zumbado M, Goethals M, Alvarez-Leon EE, et al: Inadvertent exposure to organochlorine pesticides DDT and derivatives in people from the Canary Islands (Spain). Sci Total Environ 339: 49-62, 2005.
4. Veronesi U, Boyle P, Goldhirsch A, Orecchia R and Viale G: Breast cancer. Lancet 365: 1727-1741, 2005.
5. Dumitrescu RG and Cotarla I: Understanding breast cancer risk - where do we stand in 2005? J Cell Mol Med 9: 208-221, 2005.
6. Freisinger F and Domchek SM: Clinical implications of low-penetrance breast cancer susceptibility alleles. Curr Oncol Rep 11: 8-14, 2009.
7. Sharp L and Little J: Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGE review. Am J Epidemiol 159: 423-443, 2004.
8. Rustum YM, Harstrick A, Cao S, et al: Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin Oncol 15: 389-400, 1997.
9. Kawakami K, Omura K, Kanehira E and Watanabe Y: Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 19: 3249-3252, 1999.
10. Zhai X, Gao J, Hu Z, et al: Polymorphisms in thymidylate synthase gene and susceptibility to breast cancer in a Chinese population: a case-control analysis. BMC Cancer 6: 138, 2006.
11. Ko KH, Kim NK, Yim DJ, et al: Polymorphisms of 5,10-methylenetetrahydrofolate reductase (MTHFR C677T) and thymidylate synthase enhancer region (TSER) as a risk factor of cholangiocarcinoma in a Korean population. Anticancer Res 26: 4229-4233, 2006.
12. Kim YI: Folate and carcinogenesis: evidence, mechanisms, and implications. J Nutr Biochem 10: 66-88, 1999.
13. Goyette P, Sumner JS, Milos R, et al: Human methylenetetrahydrofolate reductase: isolation of cDNA mapping and mutation identification. Nat Genet 7: 551, 1994.
14. Frosst P, Blom HJ, Milos R, et al: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10: 111-113, 1995.
15. Macis D, Maisonneuve P, Johansson H, et al: Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case-control study and a pooled meta-analysis. Breast Cancer Res Treat 106: 263-271, 2007.
16. Boccia S, Boffetta P, Brennan P, et al: Meta-analyses of the methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and risk of head and neck and lung cancer. Cancer Lett 273: 55-61, 2009.
17. Esteller M, Garcia A, Martinez-Palones JM, Xercavins J and Reventos J: Germ line polymorphisms in cytochrome-P450 1A1 (C4887 CYP1A1) and methylenetetrahydrofolate reductase (MTHFR) genes and endometrial cancer susceptibility. Carcinogenesis 18: 2307-2311, 1997.
18. Graziano F, Kawakami K, Ruzzo A, et al: Methylenetetrahydrofolate reductase 677C/T gene polymorphism, gastric cancer susceptibility and genomic DNA hypomethylation in an at-risk Italian population. Int J Cancer 118: 628-632, 2006.
19. Iacopetta B, Heyworth J, Girschik J, Grieu F, Clayforth C and Fritschi L: The MTHFR C677T and DeltaDNMT3B C-149T polymorphisms confer different risks for right- and left-sided colorectal cancer. Int J Cancer 125: 84-90, 2009.
20. Pereira TV, Rudnicki M, Pereira AC, Pombo-de-Oliveira MS and Franco RF: 5,10-Methylenetetrahydrofolate reductase polymorphisms and acute lymphoblastic leukemia risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15: 1956-1963, 2006.
21. Borresen-Dale AL: TP53 and breast cancer. Hum Mutat 21: 292-300, 2003.
22. Papadakis EN, Dokianakis DN and Spandidos DA: p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 3: 389-392, 2000.
23. Damin AP, Frazzon AP, Damin DC, et al: Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk. Cancer Detect Prev 30: 523-529, 2006.
24. Dumont P, Leu JI, Della Pietra AC III, George DL and Murphy M: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33: 357-365, 2003.
25. Harris N, Brill E, Shohat O, et al: Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol 6: 4650-4656, 1986.
26. Xu Y, Yao L, Ouyang T, et al: p53 codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res 11: 7328-7333, 2005.
27. Koushik A, Platt RW and Franco EL: p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol Biomarkers Prev 13: 11-22, 2004.
28. Suspitsin EN, Buslov KG, Grigoriev MY, et al: Evidence against involvement of p53 polymorphism in breast cancer predisposition. Int J Cancer 103: 431-433, 2003.
29. Zhang ZW, Laurence NJ, Hollowood A, et al: Prognostic value of TP53 codon 72 polymorphism in advanced gastric adenocarcinoma. Clin Cancer Res 10: 131-135, 2004.
30. Borst P and Elferink RO: Mammalian ABC transporters in health and disease. Annu Rev Biochem 71: 537-592, 2002.
31. Schinkel AH: The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 8: 161-170, 1997.
32. Hitchins RN, Harman DH, Davey RA and Bell DR: Identification of a multidrug resistance associated antigen (P-glycoprotein) in normal human tissues. Eur J Cancer Clin Oncol 24: 449-454, 1988.
33. Hoffmeyer S, Burk O, von Richter O, et al: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97: 3473-3478, 2000.
34. Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV and Gottesman MM: Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res 67: 9609-9612, 2007.
35. Zubor P, Lasabova Z, Hatok J, Stanclova A and Danko J: A polymorphism C3435T of the MDR-1 gene associated with smoking or high body mass index increases the risk of sporadic breast cancer in women. Oncol Rep 18: 211-217, 2007.
36. Turgut S, Yaren A, Kursunluoglu R and Turgut G: MDR1 C3435T polymorphism in patients with breast cancer. Arch Med Res 38: 539-544, 2007.
37. Cabrera de Leon A, Rodriguez Perez Mdel C, Almeida Gonzalez D, et al: Presentation of the 'CDC de Canarias' cohort: objectives, design and preliminary results. Rev Esp Salud Publica 82: 519-534, 2008.
38. Jakobsen A, Nielsen JN, Gyldenkerne N and Lindeberg J: Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 23: 1365-1369, 2005.
39. Salgado J, Zabalegui N, Gil C, Monreal I, Rodriguez J and Garcia-Foncillas J: Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer. Oncol Rep 17: 325-328, 2007.
40. Russo A, Corsale S, Cammareri P, et al: Pharmacogenomics in colorectal carcinomas: future perspectives in personalized therapy. J Cell Physiol 204: 742-749, 2005.
41. Iacopetta B, Grieu F, Joseph D and Elsaleh H: A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 85: 827-830, 2001.
42. Marsh S, Collie-Duguid ES, Li T, Liu X and McLeod HL: Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 58: 310-312, 1999.
43. Stevens VL, McCullough ML, Pavluck AL, et al: Association of polymorphisms in one-carbon metabolism genes and post-menopausal breast cancer incidence. Cancer Epidemiol Biomarkers Prev 16: 1140-1147, 2007.
44. Deligezer U, Akisik EE and Dalay N: Homozygosity at the C677T of the MTHFR gene is associated with increased breast cancer risk in the Turkish population. In Vivo 19: 889-893, 2005.
45. Lee SA, Kang D, Nishio H, et al: Methylenetetrahydrofolate reductase polymorphism, diet, and breast cancer in Korean women. Exp Mol Med 36: 116-121, 2004.
46. Hekim N, Ergen A, Yaylim I, et al: No association between methylenetetrahydrofolate reductase C677T polymorphism and breast cancer. Cell Biochem Funct 25: 115-117, 2007.
47. Tao MH, Shields PG, Nie J, et al: DNA promoter methylation in breast tumors: no association with genetic polymorphisms in MTHFR and MTR. Cancer Epidemiol Biomarkers Prev 18: 998-1002, 2009.
48. Chou YC, Wu MH, Yu JC, et al: Genetic polymorphisms of the methylenetetrahydrofolate reductase gene, plasma folate levels and breast cancer susceptibility: a case-control study in Taiwan. Carcinogenesis 27: 2295-2300, 2006.
49. Zintzaras E: Methylenetetrahydrofolate reductase gene and susceptibility to breast cancer: a meta-analysis. Clin Genet 69: 327-336, 2006.
50. Justenhoven C, Hamann U, Pierl CB, et al: One-carbon metabolism and breast cancer risk: no association of MTHFR, MTR, and TYMS polymorphisms in the GENICA study from Germany. Cancer Epidemiol Biomarkers Prev 14: 3015-3018, 2005.
51. Beckman G, Birgander R, Sjalander A, et al: Is p53 polymorphism maintained by natural selection? Hum Hered 44: 266-270, 1994.
52. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE and Gottesman MM: P-glycoprotein: from genomics to mechanism. Oncogene 22: 7468-7485, 2003.
53. Penson RT, Oliva E, Skates SJ, et al: Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol 93: 98-106, 2004.
54. Siddique MM, Balram C, Fiszer-Maliszewska L, et al: Evidence for selective expression of the p53 codon 72 polymorphs: implications in cancer development. Cancer Epidemiol Biomarkers Prev 14: 2245-2252, 2005.
55. Kalemi TG, Lambropoulos AF, Gueorguiev M, Chrisafi S, Papazisis KT and Kotsis A: The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. Cancer Lett 222: 57-65, 2005.
56. Klug SJ, Wilmotte R, Santos C, et al: TP53 polymorphism, HPV infection, and risk of cervical cancer. Cancer Epidemiol Biomarkers Prev 10: 1009-1012, 2001.
57. Santos AM, Sousa H, Catarino R, et al: TP53 codon 72 polymorphism and risk for cervical cancer in Portugal. Cancer Genet Cytogenet 159: 143-147, 2005.
58. Sjalander A, Birgander R, Hallmans G, et al: p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 17: 1313-1316, 1996.
59. Madeleine MM, Shera K, Schwartz SM, et al: The p53 Arg72Pro polymorphism, human papillomavirus, and invasive squamous cell cervical cancer. Cancer Epidemiol Biomarkers Prev 9: 225-227, 2000.
60. Klaes R, Ridder R, Schaefer U, Benner A and von Knebel Doeberitz M: No evidence of p53 allele-specific predisposition in human papillomavirus-associated cervical cancer. J Mol Med 77: 299-302, 1999.
61. Rezza G, Giuliani M, Garbuglia AR, et al: Lack of association between p53 codon-72 polymorphism and squamous intra-epithelial lesions in women with, or at risk for, human immuno-deficiency virus and/or human papillomavirus infections. Cancer Epidemiol Biomarkers Prev 10: 565-566, 2001.
62. Mabrouk I, Baccouche S, El-Abed R, et al: No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann NY Acad Sci 1010: 764-770, 2003.
63. Arbel-Alon S, Menczer J, Feldman N, Glezerman M, Yeremin L and Friedman E: Codon 72 polymorphism of p53 in Israeli Jewish cervical cancer patients and healthy women. Int J Gynecol Cancer 12: 741-744, 2002.